Of direct interest to pancreatic cancers, which have very high penetrance of KRAS mutations, targeting metabolic enzymes has been shown to be effective in treatment of KRAS mutant tumours in pre-clinical models of lung cancer [12]. This evidence concerns the gene KRAS and lung cancer.